Archive for the Kineta Press Release Category

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies Kineta Immuno-Oncology to receive $15 million upfront and will be eligible to receive up to $505 million in potential research, development and sales milestone payments Research collaboration focused on developing small molecules that

Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech Collaboration to develop a first-in-class α9/α10 nicotinic acetylcholine receptor antagonist for the treatment of chronic pain Kineta to receive undisclosed upfront payment and up to $359 million in additional development and commercial milestones.

Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference SEATTLE, WA, January 22, 2018 – Kineta Immuno-oncology, LLC, a biotechnology company focused on developing disruptive technologies to turn cold tumors hot, today announced that they have been invited to present at the Immuno-Oncology

Kineta to Present at Symposium on Pandemic Preparedness LHF-535 Lassa fever antiviral and vaccine adjuvant program to be highlighted Seattle, WA, June 12, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced Kineta Vice President of R&D and Head of

Kineta to Present at Symposium on Next-Generation Therapeutics for the Treatment of Pain Seattle, WA, April 25, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced Kineta CEO Shawn Iadonato has been invited to present at the Next-Generation Therapeutics for

Kineta to Present at the Planet MicroCap Showcase 2017 Seattle, WA, April 21, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced the company has been invited to present at the inaugural Planet MicroCap Showcase being held on April 26-28,

Kineta to Present at the 24th Annual Future Leaders in the Biotech Industry Conference New Advances in Chronic Pain Program to be Highlighted Seattle, WA, April 5, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced the company has been